NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
IMCIVREE (setmelanotide) by Rhythm Pharmaceuticals is melanocortin 4 receptor agonists [moa]. Approved for genetic obesity, hypothalamic obesity, obesity associated with defects in leptin-melanocortin pathway and 5 more indications. First approved in 2020.
Drug data last refreshed 19h ago
Mechanism of Action
Melanocortin 4 Receptor Agonists
Pharmacologic Class:
Melanocortin 4 Receptor Agonist
Indications (8)
Worked on IMCIVREE at Rhythm Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.